Summary of Significant Accounting Policies - Additional Information (Details)	3 Months Ended		12 Months Ended
	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2024 USD ($) Segment	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Feb. 28, 2019 USD ($)
Summary Of Significant Accounting Policies [Line Items]
Off-balance sheet concentrations of credit risk, description			The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts, or other hedging arrangements.
Research and development expenses			$ 217,564,000	$ 268,823,000	$ 285,885,000
Goodwill	$ 140,627,000	$ 140,627,000	140,627,000	$ 140,627,000
Amortization of intangible asset			0
Impairments of intangible asset			$ 0
Expected dividend yield			0.00%	0.00%	0.00%
Number of operating segment | Segment			1
Lab Equipment and Leasehold Improvements
Summary Of Significant Accounting Policies [Line Items]
Research and development expenses	1,900,000	$ 7,000,000
Acquisition Agreement | Cobalt Biomedicine, Inc
Summary Of Significant Accounting Policies [Line Items]
Goodwill	$ 140,600,000		$ 140,600,000			$ 140,600,000
Impairments of goodwill			$ 0
Minimum
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful life	3 years		3 years
Maximum
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful life	5 years		5 years